Trait: complication

Experimental Factor Ontology (EFO) Information
Identifier EFO_0009518
Description Any disease or disorder that occurs during the course of, or because of, another disease, treatment, or procedure. [ NCI ]
Trait category
Other disease
Mapped terms 6 mapped terms
  • ICD10:T79
  • ICD10:T80
  • ICD10:T81
  • ICD10:T87
  • ICD10:T88
  • NCIt:C2959
Child trait(s) device complication

Associated Polygenic Score(s)

Filter PGS by Participant Ancestry
Individuals included in:
G - Source of Variant Associations (GWAS)
D - Score Development/Training
E - PGS Evaluation
List of ancestries includes:
Display options:
Ancestry legend
Multi-ancestry (including European)
Multi-ancestry (excluding European)
African
East Asian
South Asian
Additional Asian Ancestries
European
Greater Middle Eastern
Hispanic or Latin American
Additional Diverse Ancestries
Not Reported
Note: This table shows all PGS for "complication" and any child terms of this trait in the EFO hierarchy by default.
Polygenic Score ID & Name PGS Publication ID (PGP) Reported Trait Mapped Trait(s) (Ontology) Number of Variants Ancestry distribution
GWAS
Dev
Eval
Scoring File (FTP Link)
PGS000870
(CFRD_18)
PGP000214 |
Aksit MA et al. J Clin Endocrinol Metab (2020)
Cystic fibrosis related diabetes complication 18
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000870/ScoringFiles/PGS000870.txt.gz
PGS004500
(disease.T84.score)
PGP000561 |
Jung H et al. Commun Biol (2024)
T84 (Complications of internal orthopaedic prosthetic devices, implants and grafts) device complication 1,059,939
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004500/ScoringFiles/PGS004500.txt.gz
PGS004570
(meta.T84.score)
PGP000561 |
Jung H et al. Commun Biol (2024)
T84 (Complications of internal orthopaedic prosthetic devices, implants and grafts) device complication 1,059,939
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004570/ScoringFiles/PGS004570.txt.gz

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM)
Evaluated Score PGS Sample Set ID
(PSS)
Performance Source Trait PGS Effect Sizes
(per SD change)
Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM002417 PGS000870
(CFRD_18)
PSS001093|
Ancestry Not Reported|
591 individuals
PGP000214 |
Aksit MA et al. J Clin Endocrinol Metab (2020)
Reported Trait: Cystic-fibrosis related diabetes onset HR: 1.35 AUROC: 0.5798 PCs(1-4)
PPM020615 PGS004500
(disease.T84.score)
PSS011364|
European Ancestry|
56,192 individuals
PGP000561 |
Jung H et al. Commun Biol (2024)
Reported Trait: T84 (Complications of internal orthopaedic prosthetic devices, implants and grafts) OR: 1.12485
PPM020685 PGS004570
(meta.T84.score)
PSS011364|
European Ancestry|
56,192 individuals
PGP000561 |
Jung H et al. Commun Biol (2024)
Reported Trait: T84 (Complications of internal orthopaedic prosthetic devices, implants and grafts) OR: 1.14151

Evaluated Samples

PGS Sample Set ID
(PSS)
Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS001093 All individuals had cystic fibrosis with either 2 severe CFTR mutations and/or clinically diagnosed exocrine pancreatic insufficiency. Cases are individuals with cystic fibrosis related diabetes (CFRD).Phenotypes were obtained from extracted medical charts and CF Foundation Patient Registry through 2011. CFRD was defined by clinician diagnosis of diabetes plus insulin treatment for at least 1 year. The onset of CFRD was defined as the date at which insulin was started, if it was subsequently continued for at least 1 year. In approximately 50% of the participants, independent laboratory data (such as oral glucose tolerance test or hemoglobin A1c) were able to independently confirm the diagnosis of CFRD. Diabetes data were censored at the last clinic visit or date of solid organ transplant.
[
  • 204 cases
  • , 387 controls
]
,
54.82 % Male samples
Mean = 22.7 years Not reported JHU
PSS011364 56,192 individuals European UKB